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1/6/15 
 
Dimitri Michael Kullmann, MD, PhD; Editor-in-Chief 
Brain 
 
Dear Dr. Kullmann,  
 
    Please find enclosed our revised manuscript entitled “CORTICOSTEROIDS 
COMPROMISE SURVIVAL IN GLIOBLASTOMA” for consideration to be published as a 
research article in Brain.  We appreciate the advice and comments provided by the reviewers and 
editor.  
 
We have attached a detailed list of changes we have made in manuscript, and point-by-point 
responses to the referees’ and editor’s concerns. By addressing the majority of these points, and 
incorporating their suggestions in the text of manuscript, we feel that the paper is now 
considerably stronger.   
 
This work represents a major breakthrough in our understanding of glioblastoma clinical 
management. Currently the majority of glioblastoma patients receive corticosteroids during 
radiation. However, our work suggests that this standard of care is counterproductive and 
alternatives to corticosteroids during radiation should be developed.  This paper is the most 
extensive work published on this topic and includes modeling and mechanistic studies. It is 
likely to be highly cited as the standard of care for this disease is adjusted." 
 
    The manuscript contains 8 figures, total of 8 supplementary figures and tables. All authors 
have read and approved the final version of the manuscript. We feel that this work will be of 
broad interest to the readers of Brain because it identifies DEX use during radiotherapy as an 
independent indicator of shorter survival and proposes alternative anti-edema therapy that does 
not compromise radiation efficacy. 
 
Thank you for your careful consideration of our work.  
 
Sincerely yours,  
 
Dolores Hambardzumyan, PhD 
Eric C Holland, MD, PhD 
Michael Weller, MD, PhD 
 
MAJOR POINTS 
 
COMMENT: The authors show that application of high doses of DEX to GBM-patients is 
associated with an inferior clinical outcome; they also discuss that higher concentrations of DEX 
are generally given to patients with inferior clinical perspective. Hence, larger sets of patients 
were statistically analysed to separate DEX-mediated detrimental effects from other 
clinical aspects (extent of resection, age, neurological symptoms and radiation dose). In some 
retrospective analyses (but not in all studies) DEX was an independent adverse factor. Due to the 
difficulties to assess the role of DEX from clinical samples alone the animal experiments are 
highly important to support the working hypothesis that DEX indeed is causative for reduced 
overall survival. However, the animal model reflects basically one GBM subtype (proneural 
GBM), which can differ in terms of radiation- and chemo-sensitivity from other GBM-subtypes. 
Therefore it will be important to see if the statistical analysis of clinical trials still holds, when 
the effects of DEX are studied in cohorts of patients with proneural GBM. 
 
RESPONSE: We do appreciate the reviewer’s suggestion, but unfortunately we do not have the 
information on the Verhaak subtypes in any of these cohorts.  
 
 
COMMENT: The authors explain the adverse effect of DEX-application by the reduced radio-
sensitivity of glioma cells: it is speculated that GBM cells have reduced proliferativity (and 
therefore potentially reduced radiosensitivity) after DEX-application. This view is partly 
supported by data from an expression array showing that a (relatively small) number of cell-
cycle regulatory genes is down-modulated in gliomas from DEX-treated mouse models, as 
compared to controls. This is likely to be over-simplistic and other, parenchymal effects of DEX-
treatment need to be taken into consideration: DEX blunts the immune response but immune 
effects were not investigated. It is necessary to study the number of tumour associated myeloid 
cells and angiogenesis in DEX-treated glioma bearing mice, as already done for B20-treated 
models. All potential effects of DEX on the vasculature were not addressed - although the main 
reason for DEX treatment is edema-relief. It is necessary to study the number of tumour 
associated myeloid cells and angiogenesis in DEX-treated glioma bearing mice, as already done 
for B20-treated models. This is especially important since in vitro experiments did not show any 
effects of radiation-treatment in glioma cell-cycle progression. 
 
 
RESPONSE: We are thankful for these suggestions and we do agree with reviewer about the 
complexity of DEX effects in vivo and the importance of looking at stromal effects of DEX since 
we did not see difference in DEX effects on proliferation in vitro.  
 
Per reviewer’s suggestion we have looked at the numbers of infiltrated tumor-associated 
microglia/macrophages (myeloid cells) in response to either DEX or VEGFA antibody treatment. 
Microglia/macrophages are the major immune infiltrates in both murine and human 
glioblastoma. Others and we have previously demonstrated that microglia/macrophages can 
contribute up to 20-30 % of the total tumor mass (Feng et al., 2015; Hambardzumyan et al., 
2015). While we saw a significant increase in Iba1 positive microglia/macrophage infiltration in 
B20-4.1.1 treated mice when compared to vehicle, no difference was observed between DEX-
treated and vehicle treated tumors in our treatment paradigm (incorporated as a new 
Supplemental Fig. 3C).   
 
To address the role of DEX in edema relief in our mouse model, we developed a novel T2 
weighted MRI assay described below. To our surprise we were unable to find studies looking at 
the edema effects of DEX using mouse models of brain tumors. Unfortunately it was not feasible 
to directly measure edema in the mouse model using techniques such as MRI-FLAIR. Rather, we 
developed an alternative strategy using T2 MRI based on the principle that decreasing edema 
would allow glioma-bearing mice to survive with larger tumor volumes compared to vehicle 
treated animals. Therefore, one would expect untreated animals would develop symptoms of 
increased intracranial pressure with a smaller tumor volume than DEX or B20-4.1.1 treated 
animals. To address this, we evenly distributed animals into vehicle or DEX treated cohorts 
based on initial T2-weight MRI tumor volume to ensure equal distribution of baseline tumor 
volumes. After the initial MRI tumor-bearing mice were then treated for 6 constitutive days with 
10 mg/Kg DEX or vehicle (solvent for DEX). After the completion of treatment mice were 
followed for neurological signs of tumor burden that were used to determine the survival 
endpoint in humane fashion and accordance with IACUC protocols. Right before sacrificing 
each symptomatic tumor-bearing mouse was re-imaged again in order to determine the volume 
that caused the neurological signs. Similar to the results observed with B20, DEX treated mice 
lived longer with larger tumors compared to controls. The new data are now included as (Fig. 
6A,-D).  
 
To examine potential effects of DEX on angiogenesis, we examined the effect DEX treatment had 
on total vessel area or average vessels size. In contrast to B20 treatment, we did not see 
significant changes in either total vessel area or average vessel size in the DEX treated animals. 
The new data are now incorporated in Figure 6E-F. 
 
COMMENT: A study cited in the present manuscript (J Clin Oncol. 2015 Sep 1;33(25):2735-
44) showed that concomitant radio-chemotherapy and anti-angiogenesis (with the VEGF-A 
blocker bevacizumab) prolonged overall survival in patients with proneural GBM. This effect 
cannot be seen in the (proneural) glioma mouse model. Is there an explanation for the differences 
between preclinical models and clinical data? 
 
RESPONSE: The Sandmann paper is very interesting, but hypothesis-generating at best. It 
requires independent confirmation. Moreover, this finding is a group effect and by no means 
predicts that all proneural-like glioblastomas would benefit from Bevacizumab. Besides, the 
primary goal of our murine studies was not to determine anti-tumor or the effects of B20-4.1.1 
when combined with RT on survival of the tumor-bearing mice. Our primary goal was to 
determine whether we can achieve the anti-edema effect of B20-4.1.1 using low dose and short 
treatment paradigm. Understanding how blocking VGEFA in PN hGBM enhances RT efficacy is 
beyond the scope of this manuscript and will require different primary goals and set of 
experiments and different doses of B20-4.1.1 and longer time of treatment that may be needed to 
achieve maximum anti-cancer efficacy alone or in combination with RT.  
 
 
COMMENT: The benefits of bevacizumab on progression-free survival are discussed. 
However, it is not mentioned that the inability to detect glioma progression after bevacizumab 
treatment likely is attributed to imaging artifacts and does not reflect therapeutic effects in front-
line treatment (BMC Cancer. 2009 Dec 16;9:444). 
 
RESPONSE: This has been discussed and the reference by Verhoeff et. al., in BMC Cancer. 
2009 Dec 16;9:444 is now included in the  manuscript. Additionally, in the edema analysis of 
our mouse model (Figure 6A-D), the B20-4.1.1 tumor volumes are quantified using both T1-post 
contrast and T2 weight MRI, which has been clarified in the manuscript. our mouse model we 
have clarified  
 
COMMENT: Figure 1A: According to the results part, Figure 1A compared the overall survival 
between patients not on DEX and patients on DEX. However, it was not clear what red curve 
and black curve in the Fig.1A represented. 
 
RESPONSE: We apologize – this information has been added. 
 
COMMENT: Figure 1C: According to the result part in page 6, Fig. 1c showed that OS was 
inferior in the steroid-exposed patients.  However, the p value of the log-rank test was reported 
neither in the text nor in the figure 1c. 
 
RESPONSE: Figure 1C has a p value now.  
 
COMMENT: Also, there were 1029 GBM patients in the GNN cohort. However, in the 
figrue1c, N=462 with No-steroids group, and N=370 with steroids group. The total sample size 
of these two groups (N=832) did not equal to the cohort sample size (N=1029). 
 
RESPONSE: We have now restricted the analysis primarily to patients where the data were 
available for multivariate analysis. We hope this makes it clearer. 
 
 
COMMENT: Table S1B: In Table S1A, the result revealed that KPS, Mental status, neurologic 
functional status, surgical extent, radiation dose, RPA class were statistically significant between 
the two groups (N=522 vs. N=100). Thus, these factors should be considered in the multivariate 
analysis in Table S1B. However, only RPA class was adjusted. 
 
RESPONSE: We apologize for the confusion. 
The RPA classification is a composite that 
takes into account the various clinical 
prognostic features (age, KPS, mental status, 
neurological functioning, extent of surgery, 
and total radiation dose). When we reanalyze 
the MSKCC dataset with either a continuous 
or categorical multivariate analysis taking 
these variables into account individually, we 
find that steroid use remains statistically 
significantly and independently associated 
with survival.  For simplicity, we did not 
present that information in the manuscript, but 
are happy to include it here and can 
incorporate it into the supplemental data if 
desired.  
 
 
COMMENT: Results (Page 5, last sentence): “After adjustment, this effect remained significant 
(p=0.03).” It was not clear what factors was adjusted here. 
 
RESPONSE: For all survival analyses, adjustment factors were: Extent of surgery, age, WHO 
performance status. This was added at the first occurrence, removed later. 
 
 
COMMENT: Retrospective clinical analyzes (Page 35, the fourth paragraph): Description of the 
statistical method was not found in the MSKCC cohort. 
 
RESPONSE: We apologize for the lack of clarity, and have updated the supplemental materials 
to better describe the process.  
 
"Categorical multivariate cox regression models were constructed correlating RTOG class, 
initial chemotherapy use, and baseline corticosteroid use with clinical outcomes." 
 
 
COMMENT: Besides, patients and treatment characteristics between the groups were analyzed 
in MSKCC cohort but was not found in EORTC trial and GNN cohort.   
  
 
RESPONSE: New tables for both EORTC and GGN trial are now included as new 
Supplemental Table 2A,B, correspondingly.. 
 
 
COMMENT: Results (Page 7, the last sentence in the second paragraph): P value was not 
reported here. 
 
RESPONSE: We apologize – P value has been added 
 
COMMENT: Figure 5B: In the figure legend of figure 5 (page14), it was not clear what was 
“paired ANOVA analysis”. 
 
RESPONSE: Paired ANOVA analysis was used for analysis of results in Figure 5B. The study 
was designed to use BLI as readout of the effects of DEX on tumor proliferation at 0, 24 and 48h 
post DEX and vehicle treatments. In this study each mouse with a tumor was measured by BLI at 
start of the treatment (0 point), 24h and 48h post treatment. There is more than one repeated 
factor present in these measures (three time imaging the same mouse). In cases with the same 
samples measured a multiple times standard ANOVA can’t be used and paired ANOVA is 
recommended.  
 
COMMENT: Figure 6G: P value of the survival analysis was reported neither in the figure nor 
the figure legend. 
 
RESPONSE: We apologize –P values and median survival times have now been added. 
 
COMMENT: Previous phase II clinical trial has demonstrated dosing effect of DEX when 
combing with TTfield therapy (Wong ET et al. 2014 Cancer Med).  Are there any difference in 
the high and the low dose of DEX on patient survival? 
 
RESPONSE: The Wong et al. 2015 study raises an interesting question as to how the 
immunosuppressive effects of DEX might interfere with ongoing therapy. In addition to 
immunosuppression from DEX, RT and temozolomide are in their own right immunosuppressive, 
and it remains to be determined how strongly DEX influences the immune response as a single 
agent. Unfortunately, in our retrospective datasets we don’t have access to total cumulative dose 
of steroids used. However we do have some dose information for the EORTC dataset, which we 
have included in the manuscript. When stratified by tercile in univariate analysis, the steroid 
dose is significantly pognositc in progression free and overall survival (PFS p=0.03, HR=1.14, 
OS p=0.002, HR=1.2) . However, it is not significant when performing multivariate analysis 
(PFS p=0.45, OS p=0.23) We have also updated our manuscript to include discussion of 
the Wong et. al., reference (Wong et al., 2015). 
 
COMMENT: There are no clear molecular mechanisms proposed by the authors regarding the 
how DEX reduce the therapeutic efficacy of the anit-glioma radiation therapy. Authors proposed 
that based on another study p21 expression associated with radioresistance phenomena in GBM. 
But they did not provide any data regarding the p21 status. They demonstrated that DEX therapy 
significantly reduced the tumor burden represented by the BLI signal (Fig. 5 A&B) but the 
endpoint survival data show DEX treatment don’t have any effect (Fig 4 A). In light of these data 
it is safe to conclude that BLI data is not correct, and author should consider removing it. 
 
RESPONSE: The decrease seen with the BLI signal using E2F1-luc mouse does not represent 
decrease in tumor burden. It demonstrates a decrease in proliferation, which is in agreement 
with the staining for PCNA as well as Ki67, which now is included in the manuscript as 
Supplemental Figure 1A. Considering the treatment paradigm (only 3 days), the amount 
decrease of proliferation and lack of effect on cell death it is not surprising that DEX has no 
effect on survival of tumor-bearing mice.  
 
Previously we have tried a number of p21 antibodies to inquire if the cells high p21 are 
radioresistant. Unfortunately, p21 antiboides were unsuccessful in our model and we were 
unable to produce consistent staining that would allow us to draw conclusions.  
 
COMMENT: Even though the authors have shown that the proliferation is decreased upon DEX 
therapy represented by the percent of PCNA positive cells (Fig. 5D), the biological significant 
percent of PCNA cells decreasing about 15-20% and its role in altering the therapeutic efficacy 
of the radiotherapy was not explored. How about the DNA repair capacity during DEX therapy? 
It has been shown that DEX can alter the DNA repair gene such as MGMT (Grombacher et al. 
1996 Carcinogenesis). Authors need to explore the possible molecular mechanism. 
 
RESPONSE: This is an interesting comment based on studies using rodent hepatoma cells, but 
the proposed effect may not hold true for glioma cells: our previous studies indicated that 
dexamethasone at clinically achieved concentrations of up to 100 nM for 28 h did not modulate 
MGMT activity in any of the 12 human glioma cell lines and dexamethasone at 100 nM did not 
modulate the effects of TMZ in T98G and LNT-229 cells in acute growth inhibition or clonogenic 
cell death assays (Hermisson et al., 2006). 15-20% decrease in total PCNA when translated into 
olig2/PCNA double positive, which are the tumor cells, results in 30% decrease in glioma cell 
proliferation, which is close what we also see by BLI.  
 
 
COMMENT: Authors reported 18 genes gene signature in glioma in response to DEX. What are 
these genes? They should discuss these genes and their pathway in their discussion. 
We apologize for the oversight, supplementary table describing the genes involved and ingenuity 
pathway analysis of these genes is now included (Supplementary Table S4). Pathway analysis 
shows that the DEX gene signature is enriched for genes involved in cell cycle signaling, mitotic 
assembly, and DNA repair check points. This is now highlighted in the discussion.  
 
COMMENT: The manuscript requires careful revision. There are many careless mistakes. For 
example Fig. 7 and fig.8 are completely switched. Some of the statistics is questionable and 
require further analysis (For example Fig. 6D right graph she statistically significant even though 
the error bar seems to be overlapping). 
 
RESPONSE: We apologize for mistakes and now carefully revised the manuscript. 
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Running Title: Corticosteroids compromise survival in glioblastoma 
 
ABSTRACT 
 
Glioblastoma is the most common and most aggressive primary brain tumor (Ostrom et 
al., 2014). Standard of care consists of surgical resection followed by radiotherapy and 
concomitant and maintenance temozolomide (TMZ/RT→TMZ). Corticosteroids are 
commonly used perioperatively to control cerebral edema and are frequently continued 
throughout subsequent treatment, notably RT, for amelioration of side effects. The effects 
of corticosteroids such as dexamethasone (DEX) on cell growth in glioma models and on 
patient survival have remained controversial.  
We performed a retrospective analysis of glioblastoma patient cohorts to determine the 
prognostic role of steroid administration. A disease-relevant mouse model of 
glioblastoma was used to characterize the effects of DEX on tumor cell proliferation and 
death, and to identify gene signatures associated with these effects. A murine anti-
VEGFA antibody was used in parallel as an alternative for edema control. We applied the 
DEX-induced gene signature to the TCGA glioblastoma dataset to explore the association 
of DEX exposure with outcome. Mouse experiments were used to validate the effects of 
DEX on survival in vivo.  
Retrospective clinical analyses identified corticosteroid use during RT as an independent 
indicator of shorter survival in three independent patient cohorts. A DEX-associated gene 
expression signature correlated with shorter survival in the TCGA patient dataset. In 
glioma-bearing mice, DEX pretreatment decreased tumor cell proliferation without 
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affecting tumor cell viability, but reduced survival when combined with RT. Conversely, 
anti-VEGFA antibody decreased proliferation and increased tumor cell death, but did not 
affect survival when combined with RT.  
Clinical and mouse experimental data suggest that corticosteroids may decrease the 
effectiveness of treatment and shorten survival in glioblastoma. DEX-induced anti-
proliferative effects may confer protection from RT-and chemotherapy-induced 
genotoxic stress. This study highlights the importance of identifying alternative agents 
such as VEGF antagonists for managing edema in glioblastoma patients. Beyond the 
established adverse effect profile of protracted corticosteroid use, this analysis 
substantiates the request for prudent and restricted use of corticosteroids in glioblastoma. 
 
INTRODUCTION 
 
Dexamethasone (DEX) is a potent synthetic corticosteroid and is considered the “gold 
standard” for managing cerebral edema (Raslan and Bhardwaj, 2007). The exact 
mechanism underlying the anti-edema effects of DEX is not known, although it is widely 
believed that DEX suppresses inflammation and decreases vasogenic edema through 
partial restoration of blood-brain barrier integrity (Rovit and Hagan, 1968; Eisenberg et 
al., 1970; Kotsarini et al., 2010). It is also not clear whether DEX influences the 
effectiveness of standard DNA-damaging therapy for glioblastoma such as radiotherapy 
(RT) or alkylating agents. There are conflicting studies in vitro (Grasso et al., 1977; 
Weller et al., 1997) and in vivo (Wang et al., 2004) that show antagonism, no interaction, 
or even synergy with chemotherapy (reviewed in Piette et al., 2006). Despite uncertainty 
regarding biological efficacy in glioblastoma, DEX is effective in controlling many RT- 
and chemotherapy-induced side effects (i.e. nausea and vomiting) and is therefore 
frequently continued throughout the duration of RT. More recently, it has been observed 
that VEGF antagonists such as the antibody, bevacizumab, or the tyrosine kinase 
 4 
inhibitor, cediranib, have profound anti-edema effects, commonly obviating the need for 
steroid comedication if administered to patients. 
 
In the present study, we confirmed the use of corticosteroids early in the course of 
disease, during RT without or with chemotherapy, as an independent predictor of poor 
outcome in three independent patient cohorts. We also used disease-relevant genetically 
engineered mouse models (GEMMs) of murine glioblastoma (Hambardzumyan et al., 
2009) to show that DEX pretreatment significantly decreases survival in irradiated 
glioma-bearing mice. Finally, we report that replacing DEX with short-term VEGF 
antagonism may be the preferred alternative over corticosteroids in the initial 
management of glioblastoma. 
 
Methods 
 
Retrospective Clinical Analyses 
Three independent patients cohort were analyzed. Details are provided in the 
Supplementary Appendix.  
 
Generation of RCAS/Tva system-based PDGFB-driven and orthotopic gliomas 
6-8-week-old Ntv-a/ink4a-arf-/-, Gli-luc;Ntv-a;Ink4a-Arf-/- and N-tva/Ef-Luc mice were 
used to generate gliomas via introduction of RCAS-PDGFB-HA and RACS-shp53 
(Uhrbom et al., 2004; Hambardzumyan et al., 2009). Details are provided in the 
Supplementary Appendix. 
 
MRI scans  
T2-weighted and T1-weighted contrast-enhanced MRI scans of tumor-bearing mice were 
performed as described (Koutcher et al., 2002).  
 
Tissue Processing, Immunohistochemistry and Immunofluorescence 
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These assays were performed according to previously published protocols (Becher et al., 
2008; Hambardzumyan et al., 2008) and antibody information is provided in the 
Supplementary Appendix. 
 
Bioluminescence imaging (BLI) 
Ef-Luc mice were used for BLI studies according to published protocols (Uhrbom et al., 
2004).  Additional methodological details are provided in the Supplementary Appendix. 
 
RESULTS 
 
Retrospective clinical analyses of glioblastoma patients 
 
To investigate an association of corticosteroid use with the efficacy of therapy and 
outcome, we first performed a retrospective clinical analysis of 622 patients treated at 
Memorial Sloan Kettering Cancer Center (MSKCC). Expectedly (Stupp et al., 2005), 
patients receiving TMZ had a significantly longer median survival (15.9 vs. 12.8; 
p=0.0023). Patients not on DEX at the start of RT had a median survival of 20.6 months 
whereas patients on DEX had a survival time of 12.9 months (p<0.0001, Fig. 1A). There 
were no significant differences in age, gender, duration of symptoms, or TMZ use 
between patients that did or did not receive steroids at the start of therapy. Steroid use 
was significantly more common in patients with lower KPS, altered mental status, altered 
neurologic function, less extensive surgery, and lower radiation dosing. Accordingly, 
steroid use was significantly more common in the higher RPA groups (Table S1A). Yet, 
multivariate COX regression analysis revealed that OS was independently associated 
with RPA class, TMZ use and steroid use at the start of RT (Table S1B).  
 
Second, we also explored the association of baseline steroid use with outcome in 573 
patients from the pivotal EORTC NCIC trial that established TMZ/RT→TMZ as the new 
standard of care (Gorlia et al., 2008; Stupp et al., 2014). The use of steroids was 
correlated with the extent of resection at initial surgery (p<0.0001, Fisher test); 91% of 
patients who underwent biopsy, 74% of patients with partial resection, but only 59% of 
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patients with complete resection had steroids at baseline (Table S2A). The median dose 
administered was 12 mg for biopsied patients and 6 mg for patients with partial or 
complete resection (p>0.0001, Kruskal-Wallis test). Patients with baseline steroids had a 
lower median PFS (5.3 vs. 6.4, p<0.0001, HR=1.39). After adjustment for the extent of 
surgery (partial or complete resection vs biopsy), age (continuous), WHO performance 
status (>0 vs 0), this effect remained significant (p=0.03) stratified by treatment (Table 
S3A). This effect was borderline, non-significant in the RT arm (p=0.06, HR=1.33) 
whereas it was not significant in the TMZ/RT→TMZ arm (p=0.23, HR=1.17). The 
prognostic value of baseline steroid dose (split by tercile) was significantly overall 
stratified by treatment (p=0.03, HR=1.14) but not in multivariate analysis (p=0.45). 
Steroid dose was significant in the RT arm (p=0.004, HR=1.28) but was borderline, non-
significant in multivariate analysis (p=0.08) and was not significant in the 
TMZ/RT→TMZ arm (p=0.8, HR=1.02; p=0.88 in multivariate analysis). Altogether, 
patients with baseline steroids had a lower median OS (12 vs. 17 months, p<0.0001, 
HR=1.56) (Fig. 1B). This effect remained significant after adjustment for age, extent of 
surgery, and WHO performance status (p=0.003) and was significant in the RT arm 
(p=0.004, HR=1.52) but not in the TMZ/RT→TMZ arm (p=0.2, HR=1.2). The 
prognostic value of steroid dose at baseline, split by tercile, was significantly when 
stratified by treatment (p = 0.002, HR=1.2) but not significant in multivariate analysis (p 
= 0.23). Steroid dose was significant in the RT arm (p=0.002, HR=1.28) and in 
multivariate analysis (p=0.048). It was not significant in the TMZ/RT→TMZ arm 
(p=0.22, HR=1.11, also not significant in the multivariate model, p=0.73). Thus, steroids 
at baseline was a prognostic factor for both PFS and OS in the EORTC NCIC trial and 
higher doses of steroids were a negative prognostic factor in patients treated with RT 
alone more than in patients treated with TMZ/RT→TMZ. 
 
Third, an association between steroid administration at the start of RT and outcome was 
examined in a cohort of 832 glioblastoma patients enrolled in the German Glioma 
Network (GGN) (Table S2B). PFS and OS were inferior in steroid-exposed patients in all 
patients pooled (Fig. 1C, Fig. 2A, Table S3B) as well as in patients treated with RT plus 
chemotherapy, although not patients treated initially with RT alone (Fig. 2B-D, Table 
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S3B). The association between steroids and inferior outcome was prominent in patients 
who had received a gross total resection, notably in those treated with RT plus 
chemotherapy (Fig. 3; Table S3B). Multivariate analysis confirmed that steroid 
administration was an independent negative prognostic factor when adjusting for extent 
of resection, initial treatment, age and KPS (Table S3B). 
 
DEX, but not anti-VEGFA antibodies, compromise RT efficacy in murine glioma 
models in vivo. 
 
In order to support potential adverse effects of DEX on survival, we utilized a murine 
PDGFB-driven glioblastoma model, based on the RCAS/Tva system, a somatic cell 
specific gene transfer (Hambardzumyan et al., 2009). DEX alone had no impact on 
survival (p=0.32, Fig. 4A) whereas pretreatment with single doses of DEX for three 
constitutive days profoundly decreased the survival advantage afforded by a single 10 Gy 
dose of irradiation (p=0.03, Fig. 4B). This effect was even more pronounced when a 
fractionated irradiation schedule was used (p=0.002, Fig. 4C).  
Because of the deleterious effects of DEX on the survival benefit afforded by RT, we 
next focused on identifying an alternative to DEX to decrease edema. Inhibition of VEGF 
signaling, either with neutralizing antibodies or VEGFR-targeted kinase inhibitors, leads 
to decreased edema, which can result in improved survival of brain tumor-bearing mice 
despite persistent tumor growth (Gerstner et al., 2009; Kamoun et al., 2009). In order to 
assess whether the anti-VEGF antibody-B20-4.1.1, a murine surrogate for bevacizumab, 
interferes with the response to RT, too, we allocated tumor-bearing mice into different 
treatment groups based on gender and age. Compared to vehicle treatment, both B20-4.1.1 and RT independently prolonged survival (Fig. 4D). However, in contrast to DEX, there was no significant difference between B20-4.1.1+RT treated animals compared to RT alone, demonstrating that B20-4.1.1 treatment does not interfere with RT efficacy (p=0.86, Fig. 4D).  
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DEX responsive gene signature in gliomas. 
 
In order to broadly assess the genes and pathways that are responsive to DEX and 
identify pathways associated with treatment resistance, we utilized microarray analyses 
from untreated and DEX-treated mouse glioma samples. The data were first analyzed by 
principle component analyses (PCA) (Fig. 5A). We identified nineteen genes that were 
significantly altered (all down-regulated) in response to DEX treatment, seven of which 
were subsequently validated by quantitative real-time PCR (Fig. 5B,C). These genes 
were significant components of the cell cycle and mitotic machinery (Table S4).  
We generated a DEX-responsive signature based on the arrays described above and 
queried TCGA patient survival and expression data. Because DEX is given to essentially 
all patients prior to surgery, we predicted that they would have expression signatures 
reflecting DEX treatment. We further identified a subset of patients with a comparatively 
high expression of genes down-regulated by DEX as having tumors that are minimally 
responsive to DEX treatment (Fig. 5D). High expression was defined as greater than two 
standard deviations above the mean, which classified 13% of patients as minimally 
responsive (“Untreated-Like”; Fig. 5E). These patients had the highest expression levels 
of one or more of the DEX down-regulated genes and had a significantly longer median 
survival (p=0.008, Fig. 5F). Our TCGA analysis was suggestive of an improved survival 
for patients whose tumors reflected our untreated mouse samples compared to DEX-
treated samples.  
 
DEX treatment effects on glioma growth in vivo and in vitro 
 
One mechanistic explanation of drugs compromising RT efficacy is based on the 
phenomenon that, in general, cells are more radiosensitive when they are in G2/M and 
more radioresistant when they are in G1. Therefore if a drug induces a decrease in 
proliferation, it can potentially reduce the radiosensitivity of a population via 
redistribution of the cell cycle, leading to accumulation in G1 and decreased fractions in 
G2/M (Powell and Abraham, 1994). We have previously documented that DEX induces 
the cell cycle inhibitor p21 (Glaser et al., 2001), and overexpression of p21 is associated 
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with radioresistance in human gliomas (Kokunai and Tamaki, 1999). Accordingly, we 
next examined DEX effects on proliferation of tumor cells in vivo. We first set out to 
assess the effect of DEX on proliferation of mouse gliomas using a non-invasive 
bioluminescence (BLI) reporter. We have previously described a Ntv-a;Ef-Luc transgenic 
mouse that expresses firefly luciferase driven by the E2F1 promoter (Ef-Luc) (Uhrbom et 
al., 2004). The E2F1 transcription factor is normally activated in cell cycle progression 
during the G1/S transition and is highly active in gliomas (Parr et al., 1997). The dose of 
DEX used in the clinic for patients with high grade gliomas is variable, ranging from 0.5 
to 16 mg daily (discussed in detail in (Kostaras et al., 2014)). Considering the toxicity 
associated with higher doses of DEX and the wide range of doses used in human patients, 
we used doses closer to the lower end of the range, 0.81 mg daily, which based on dose 
translation from human studies equals approximately 10 mg/kg (Reagan-Shaw et al., 
2008). First, we confirmed that 10 mg/kg DEX was not toxic in non-tumor-bearing mice 
when given at that dose for seven days and followed for 45 days (data not shown). Next, 
tumor-bearing mice were imaged by BLI and then randomized into either vehicle or 
DEX-treated cohorts (daily DEX i.p. at 10 mg/kg) and followed for 48 h (Fig. 6A). 
Vehicle-treated mice showed no change in BLI signal (p=0.35, Fig. 6B) while there was 
a decrease in BLI with DEX treatment (p=0.0006, Fig. 6B). In our model, glioma cells 
express high levels of Olig2, which can be used to distinguish the bulk tumor from 
stromal cells (Helmy et al., 2012). To specifically address the anti-proliferative effect of 
DEX on tumor cells, we utilized immunofluorescence double staining for Olig2 and 
PCNA (Fig. 6C) and showed a specific decrease in tumor cell proliferation in DEX-
treated mice (p<0.0001, Fig. 6D), which was also confirmed with Ki67 staining, a second 
marker of proliferation (SFig. 1A). Comparing areas of necrosis and levels of the pro-
apoptotic cleaved caspase-3 revealed no significant differences between groups, 
confirming that the decrease in proliferation was due to a cytostatic effect and not due to 
overall cell loss (Fig. S1B).  
In order to further characterize the effects of DEX on proliferation in vitro, we generated 
mouse primary glioma cell cultures. When different doses of DEX were tested in brain 
tumor patients, the average concentration of DEX in tumor tissue was approximately 225 
ng/g (about 225.27 ng/ml) (Nestler et al., 2002). We chose three concentrations of DEX 
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(39.5 ng/ml=0.1 µM, 395 ng/ml=1 µM and 3950 ng/ml=10 µM). In contrast to the results 
of tumors in vivo, none of the murine cell lines tested showed a significant decrease in 
growth or viability (Fig. S2A). Next, we compared the cell cycle profile of primary 
cultures treated with or without DEX (Fig. S2B). There was a marginal increase in G1 
and a marginal decrease in G2, which may explain why we did not observe a difference 
in growth or viability. Taken together, these assays suggest that the in vivo effects of 
DEX are not recapitulated in vitro, highlighting the importance of using an in vivo system 
with an intact tumor microenvironment. These data imply that the in vivo effect of DEX 
on tumor cell proliferation is probably indirect. 
 
Effects of DEX and anti-VEGFA antibody on edema and in vivo glioma growth  
 
It has been well-documented that inhibition of VEGF signaling, either with neutralizing 
antibodies or VEGFR-targeted kinase inhibitors decreases edema, resulting in improved 
survival of brain tumor-bearing mice despite persistent tumor growth (Gerstner et al., 
2009; Kamoun et al., 2009). Therefore, we examined the tumor size at onset of 
neurological symptoms, such as seizure, lethargy, or weight loss, of vehicle, DEX, and 
B20-4.1.1 treated animals, reasoning that effective edema treatment would permit larger 
tumors at the time of onset of symptoms. Based on MRI-determined tumor volume, 
asymptomatic glioma-bearing mice were randomized into vehicle, DEX or B20-4.1.1 
treatment groups. Animals were treated with their respective agent and subsequently 
reimaged upon time of symptom development. Although DEX treatment alone offered no 
survival advantage, DEX treated animals had significantly larger tumors at the time of 
symptom onset (Fig 6B). Despite controlling edema and permitting mice to remain 
asymptomatic with larger tumors, there was no survival advantage to DEX treatment 
alone (Fig 6A). Interestingly, in B20-4.1.1 treated animals we saw a significant survival 
advantage as well as significantly larger tumors at the end point of survival than vehicle-
treated mice (Fig. 6C,D). This was also true when quantified by T1-contrast 
enhancement (SFig. 3B).  
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The effects of DEX and Anti-VEGFA antibody on tumor vasculature and associated 
myeloid cells infiltration.  
 
As both DEX and B20-4.1.1 were effective in controlling edema, we next investigated 
their effects on tumor vasculature by immunohistochemistry. Sections of mouse gliomas 
treated with vehicles and either B20-4.1.1 or DEX were stained with anti-CD31 antibody, 
which specifically labels endothelial cells of glioblastoma and normal blood vessels 
outside of the tumor area. In DEX-treated tumors we saw no changes either in total vessel 
area or average vessel size compared to vehicle (Fig. 6E,F). B20-4.1.1 tumors had 
decreases in total vessel area (p < 0.0001) and average vessel size (p=0.0076), while no 
differences were observed in non-tumor cortical areas (Fig. 6G,H, SFig. 3A).  Decrease 
in total vessel area and average vessel size induced by B20-4.1.1 was transient since 
vessels returned to their initial morphology when B20-4.1.1 was stopped (data not 
shown). We further investigated the effect of B20-4.1.1 on tumor vasculature using 
Hoechst dye leakage assays and functional vessel labeling with circulating FITC-
conjugated lectin in vehicle- and B20-4.1.1-treated tumors (Fig. 6I,J). B20-4.1.1 
decreased leaky areas compared to vehicle (Fig. 6E,F) (p=0.002).  
DEX was suggested to be immunosuppressant, as are RT and TMZ (Ellsworth and 
Grossman, 2015), and a recent correlative study suggested that DEX-treatment induced 
immune suppression could interfere with clinical efficacy of standard therapy in recurrent 
glioblastoma (Wong et al., 2015). Microglia/macrophages are the major immune 
infiltrates in both murine and human glioblastoma, accounting for up to 20-30 % of the 
total tumor mass (Feng et al., 2015; Hambardzumyan et al., 2015). 
To investigate potential immunosuppressive characteristics of DEX we looked at the 
numbers of infiltrated tumor-associated microglia/macrophages in response to either 
DEX or VEGFA antibody treatment using the myeloid lineage marker Iba1. No 
difference was observed between DEX-treated and vehicle treated tumors (SFig. 3C  
upper panel), whereas we observed a significant increase in Iba1 positive 
microglia/macrophage infiltration in B20-4.1.1 treated mice when compared to vehicle 
(SFig. 3C lower panel),  
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Anti-VEGFA antibody B20-4.1.1 decreases glioma proliferation and induces tumor 
cell death.  
 
In our mouse model, DEX treatment alone offers no survival advantage whereas B20-
4.1.1 alone consistently prolonged survival (Fig. 4A,D; Fig. 6). To examine potential 
effects on proliferation, we treated tumor-bearing mice with vehicle or B20-4.1.1 for two 
weeks (5 mg/kg B20-4.1.1 twice a week) and compared the proliferation of tumor cells 
by double staining for Olig2 and PCNA. We observed a significant decrease in 
proliferation of tumor cells in B20-4.1.1-treated samples (p <0.0001, Fig. 7A,B). 
Similarly, we confirmed this reduction in both Ki67 staining and in pH3 staining (data 
not shown). 
Next, we examined whether B20-4.1.1 promotes cell death in gliomas. B20-4.1.1 treated 
tumors had a decrease in the Olig2-positive tumor area (p=0.02, Fig. 7C,E) and an 
increase in apoptotic cells, as evidence by increased TUNEL-positivity (p=0.02, Fig. 
7D,F). To address whether it is only tumor cells or other non-neoplastic cells in the tumor 
microenvironment that are affected by B20-4.1.1 treatment, we performed 
immunofluorescence double staining for TUNEL and the tumor-specific marker Olig2, 
the endothelial cell-specific marker CD31, the microglia/macrophage-specific marker 
Iba1, or the reactive astrocyte-specific marker GFAP. In vehicle-treated tumors, 1.01% of 
TUNEL-positive cells were also Olig2-positive, which was significantly increased to 
3.55% in B20-4.1.1-treated mice (p=0.03) (Fig. S4A,B). We did not observe significant 
changes in the number of TUNEL-positive cells from the tumor microenvironment (Fig. 
S4A,B; data now shown)  
 
DISCUSSION 
 
The administration of steroids to control neurological morbidity associated with brain 
tumors has been established as a standard of care decades ago. Except for primary CNS 
lymphoma where steroids exert direct cytotoxic effects, amelioration of brain tumor-
association edema has been proposed to underlie these symptomatic effects of steroids. 
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However, these undisputed beneficial effects of steroids have to be weighed against a 
plethora of acute and long-term side effects. 
In the current study, we identified the use of corticosteroids early in the disease course, 
during RT without or with alkylating chemotherapy, as an independent predictor of poor 
outcome in three independent patient cohorts. Although higher steroid doses are 
commonly given to patients with larger tumors and more prominent neurological deficits, 
we tried to control for such unfavorable confounders as feasible. Yet, we cannot exclude 
that detrimental effects of steroids other than direct interference with RT contributed to 
the overall inferior outcome of patients exposed to steroids. Thus, steroids can contribute 
to morbidity and mortality through their direct toxicity, including steroid myopathy, 
impaired immune function, adrenal insufficiency, and bowel perforation. Our findings 
with three large independent dataset were further supported with a recent correlative 
retrospective analysis of 73 patients with glioblastoma showing that DEX use during RT 
with concurrent TMZ correlated with reduced OS and PFS (Shields et al., 2015).  
In support of a direct detrimental effect interfering with the activity of RT, we report that 
pretreatment with DEX decreased the survival benefit afforded by RT in murine gliomas. 
In these tumors, DEX decreased proliferation and the expression of many cell cycle-
related genes. Expression of these genes inversely correlated with survival in the TCGA 
glioblastoma patient dataset. Of note, these genes are primarily known or predicted to be 
involved in proliferation, either via cell mitotic assembly, cycle checkpoints, DNA 
damage response and ATM signaling. RT sensitivity varies with the position of the cells 
in the cell cycle, and in general, tumors with high cell turnover rates are the most 
radiosensitive (Hall et al., 2012). Specifically, the p21 protein is induced by DEX in 
glioma cells, slows cell cycle progression and may confer cytoprotection (Naumann et 
al., 1998; Glaser et al., 2001; Ueda et al., 2004) Further studies are warranted to more 
precisely establish interactions between DEX and these cell types and how these might 
influence the disease course. 
In pursuit of alternatives to DEX, we demonstrated that short-term treatment with a low 
dose of VEGF antibody results in decrease in the total vessel area and the average vessel 
size, decreased leakage, and symptomatic edema control, permitting mice to be 
asymptomatic from intracranial tumors with larger tumor volumes. Moreover, VEGF 
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antibody treatment did not interfere with the efficacy of RT. Our data support the use of 
anti-VEGF agents as an alternative edema management strategy for glioblastoma 
patients. Of note, although the VEGF antibody bevacizumab did not prolong survival in 
newly diagnosed glioblastoma patients when added to standard of care, it nevertheless 
strongly prolonged progression-free survival which has been attributed in part to a 
confounding effect on imaging (Verhoeff et al., 2009). Yet, these data altogether provide 
ample evidence that VEGF antagonism does not compromise the efficacy of RT in 
human patients in vivo. Moreover, a retrospective analysis of the AVAglio data 
demonstrated that patients with IDH1 wild-type proneural glioblastoma might even 
derive a survival benefit from bevacizumab in that setting (Sandmann et al., 2015).   
In conclusion, given that controlled clinical trials to address the steroid question in 
glioblastoma are unlikely to be ever performed, we believe that our retrospective clinical 
data and corresponding data from animal models provides the so far strongest evidence 
against the traditional, often uncritical use of steroids in brain tumor patients. 
 
LEGENDS 
 
Figure 1. Corticosteroid use at the start of radiotherapy (RT) without or with TMZ 
is an independent marker of poor prognosis in human glioblastoma patients from 
three independent cohorts. Overall survival of (A) MSKCC, (B) EORTC 26981/22981 
NCIC CE.3, (C) GGN patient cohorts. 
 
Figure 2. Association between steroid administration and outcome in the GGN 
cohort. PFS by steroid use in all patients (A), PFS (B) and OS (C) for patients with RT 
only as initial treatment. PFS (D) and OS (E) for patients with RT/CT as initial treatment. 
 
Figure 3. Association between steroid administration and outcome in the GGN 
cohort by extent of resection. PFS (A) and OS (B) by steroid use in GGN patients with 
gross total resection. PFS (C) and OS (D) by steroid use in GGN patients without gross 
total resection. 
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Figure 4. DEX but not anti-VEGFA antibody treatment decreases survival after RT. 
Mice with PDGF-driven gliomas were randomized into either DEX or untreated cohorts, 
and on the third day were further randomized into either (A) non-irradiated, (B) single 
dose, or (C) fractionated RT groups. DEX alone had no impact on survival, but decreased 
the efficacy of both single dose and fractionated RT. The cartoon at the bottom of each 
survival plot depicts the treatment schedule. (D) Kaplan-Meier survival curves for mice 
randomized into vehicle, B20-4.1.1 treatment, RT alone, or RT+B20.4.1.1 groups. 
Schematic illustrations of treatment paradigms for A-C are below and for D on the right 
together with experimental groups. p values were calculated using a Log-rank (Mantel-
Cox) test, *p<0.05, **p<0.01, ****p<0.0001. 
 
Figure 5. DEX-treated gliomas have down-regulation of cell cycle genes, which 
correlates with poor prognosis in the TCGA dataset. (A) 3D - PCA plot showing 
control- (black) and DEX- (red) treated samples (n=4 per each group). The axes of the  
plot denote the variation accounted for by each component. (B) Heat map and supervised 
clustering of arrays based on the most significant 25 probes, representing 19 genes. All of 
the genes are strongly down-regulated in DEX-treated samples. (C) Validation of seven 
DEX down-regulated genes by qRT-PCR. All samples are normalized to TBP expression 
levels. ****p <0.0001 for all comparisons, determined using one-way ANOVA. (D) 
Representative distribution of TCGA-samples by Abnormal Spindle-like, Microcephaly-
associated (ASPM) gene expression, based on z-scores normalized to diploid samples. 
Patients with elevated expression levels more than two standard deviations above the 
mean were considered minimally DEX-responsive. This process was repeated for the 
most significantly DEX-regulated genes. (E) Distribution of patients based on 
classifications as described above, showing the number of patients with high expression 
of 0-15 DEX-regulated genes. The graph (F) does not include the 423 (87%) patients 
who had no genes expressed above our threshold. This more clearly shows the 
distribution of minimally DEX-responsive patients. (F) Minimally DEX-responsive 
patients have significantly better overall survival rates (18.3 vs. 13.7 months). p values 
were calculated using a Log-rank (Mantel-Cox) test, **p<0.01, *p<0.05.  
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Figure 6. DEX suppresses proliferation of glioma cells in PDGF-driven murine 
gliomas. Representative bioluminescence images (BLI) of individual Ntv-a/Ef-Luc mice 
with PDGF-driven gliomas treated with either vehicle or with DEX at 10 mg/kg (B). 
DEX-treated mice received three total doses: at day 0 (immediately after BLI), day 1, and 
day 2 (1 hour pre-BLI). The bar graph shows that DEX treatment significantly decreased 
BLI output whereas vehicle treatment did not. Each group had n = 3 mice, values were 
normalized to day 0. (C) Representative tumor sections and (D) quantification of glioma 
proliferation using Olig2 expression as a glioma cell marker and PCNA as a proliferative 
marker. Data in upper panel are presented as the % of PCNA positive cells in total (based 
on nuclei count by DAPI per field) and the lower panel is the % of PCNA/Olig2 double 
positive cells in total PCNA positive cells per field. p values were calculated by paired 
ANOVA analyses within each group, **p<0.01, ***p<0.001 for B by unpaired Student’s 
t-test, ****p<0001 for D. Scale bars: 50 μm in C. 
 
Figure 7. Effects of anti-VEGF versus DEX treatment on blood vessel density, 
leakiness, tumor size and survival 
(A,C) Kaplan-Meier survival curves for (A) DEX treatment vs. vehicle (n=7 and 7 for 
vehicle and DEX, respectively) and (C) B20-4.1.1 vs vehicle (n=14 and 15, respectively). 
Groups were matched based on initial asymptomatic T2-MRI tumor volume. (B,D) 
Representative images and quantification of T2-weighted MRI scans at time of symptom 
development for (B) vehicle- vs DEX treated mice (n=6 and 6, respectively) and (D) 
vehicle- and B20-4.1.1-treated mice (n=4 and 5, respectively). (E) Representative images 
and quantification (F) of CD31 staining of a tumor region after the administration of 
vehicle or DEX. (G)Representative images and quantification (H) of CD31 staining of a 
tumor region after the administration of vehicle or B20-4.1.1 (I) Illustration and 
representative images of a Hoechst dye leakage assay and functional vessel labeling with 
circulating FITC-conjugated lectin in vehicle- and a B20-4.1.1-treated tumors. (F) 
Corresponding quantification of Hoechst-positive area in B20-4.1.1-treated tumors 
compared to vehicle-treated tumors. p values were calculated using an unpaired Student’s 
t-test, *p<0.05 **p < 0.01, ****p < 0.0001: Scale bars: 50 μm for A and C and 100 μm 
for E.  
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Figure 8. B20-4.1.1 decreases proliferation and increases cell death in murine 
PDGF-driven gliomas. (A) Representative tumor sections and (B) quantification bar 
graphs of glioma proliferation using Olig2 expression as a glioma cell marker and PCNA 
as a proliferative marker. There was a significant reduction in the proliferation of glioma 
cells after B20-4.1.1 treatment. (C) Representative images of Olig2 staining in tumor 
sections showing decreased staining in B20-4.1.1-treated mice compared to vehicle-
treated mice. (D) Representative images of TUNEL staining in vehicle- and B20-4.1.1-
treated tumors and (E) corresponding quantification of Olig2-positive area (F) and 
TUNEL-positive cells in response to B20-4.1.1 treatment. P values were calculated by an 
unpaired Student’s t-test, *p < 0.05, ***p < 0.001, ****p<0.0001. Scale bars: 50 μm for 
A, C and D. 
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EXTENDED MATERIALS AND METHODS  
 
Ethical statement 
All animal experiments were conducted in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were 
approved by the Institutional Animal Care and Use Committees of the Lerner Research Institute 
(LRI), Cleveland Clinic and of Memorial Sloan-Kettering Cancer Center. The approved protocol 
numbers are 2013-1029 (LRI, last approved June 25, 2013), MSKCC-00-11-189 and Emory 
University 2003253 (EU last approved on September 15th 2015). 
 
Cell cultures and transfections  
DF-1 cells were purchased from ATCC (Manassas, VA). Cells were grown at 39°C in 
accordance with the manufacturer’s instructions. Transfections with RCAS-PDGFB-HA and 
RCAS-sh-p53 were performed using a Fugene 6 transfection kit (# 11814443001; Roche, 
Mannheim, Germany). 
 
Generation of RCAS/Tva system-based PDGFB-driven  
Ntv-a/ink4a-arf-/- and Gli-luc;Ntv-a;Ink4a-Arf-/- mice (6-8 weeks old) were sedated with 
intraperitoneal (i.p.) injections of ketamine (0.1 mg/g) and xylazine (0.02 mg/g). One microliter 
of 5 x 104 RCAS-PDGFB-HA-transfected DF-1 cell suspension was delivered from a Hamilton 
syringe with a 30-gauge needle attached to a stereotactic fixation device (Stoelting, Wood Dale, 
IL). For the N-tva/Ef-Luc, we injected 1 µL of a 1:1 mixture of 105 cells containing an equal 
mixture of RCAS-PDGFB-HA and RACS-shp53. Coordinates in the right frontal striatum were 
determined according to a mouse brain atlas1 (coordinates from bregma: A/P 1.7 mm, Right- 0.5 
mm, and depth 1.5 mm). Mice were sacrificed 4-6 weeks after injections, a time point after they 
had developed tumors. Mice were monitored and sacrificed when they displayed signs of tumor 
development (lethargy, weight loss). 
 
Dexamethasone (DEX) treatment 
Glioma-bearing mice received intraperitoneal (i.p.) injections of 10 mg/kg DEX (DexaJect, NDC 
#11695-4017-1, Butler Schein) and Sigma (D4902-25MG). Either upon becoming symptomatic 
(Figure 4A,B,C) or based on MRI scans (Figure 6H,I), mice were treated with 10 mg/kg of DEX 
via i.p. injection for 3, 7 or 6 days. The DEX concentration in brain tissue is expected to be ~1 
μM when mice are treated with 10 mg/kg 2,3.  
 
B20-4.1.1 treatment 
B20-4.1.1 (Genentech, CA) is an anti-VEGF-A monoclonal antibody (mAb) that inhibits VEGF-
A interactions with VEGF receptors (VEGFR1 and VEGFR2) in vitro4 and has been shown to 
inhibit VEGF-A-mediated angiogenesis in vivo5,6. For in vivo experiments, dilutions were made 
in sterile saline. For most mouse experiments, we used 5 mg/kg 2x/week dosing, or alternatively 
for short experiments we used 5 mg/kg for 1 week (only 2 doses). Vehicle-treated mice received 
the same volume of saline in 10 μl volume per g/body weight. For the survival experiment in 
Figure 5, B20-4.1.1 was used at a dose of 7.5 mg/kg.  
For Figure 4D, four different treatment groups were included: vehicle-treated, B20-4.1.1 
treatment alone (5 mg/kg, 2x/week), RT alone (20 Gy treatment, radiation was dosed at 2 Gy/day 
for five days followed by 2 days off and again dosed for another 5 days) and B20-4.1.1 treatment 
combined with RT simultaneously. During treatment, mice were weighed daily to assess toxicity 
from a single treatment or a combination of treatments, followed by weighing every other day to 
track the development of tumor-associated neurological signs (severe weight loss >15%, 
seizures, lethargy, lack of grooming), which was the end point of survival. 
 
MRI scans  
For T2-weighted MRI scans, each animal was first anesthetized with 1-2% isoflurane in oxygen 
and positioned at the isocenter of a 9.4T Bruker Biospec small animal MRI scanner (Bruker Inc., 
Billerica, MA) at the Center for Imaging Research at Case Western Reserve University 
(CWRU), Cleveland, OH for Figure 6G and H and 9.4T Bruker Biospec at Emory University 
small animal imaging core (Figure 6H,I) (Atlanta, GA). After initial localizer scans, a high-
resolution coronal proton-density RARE (Rapid Acquisition with Relaxation Enhancement) 
acquisition was obtained for each animal (TR/TE = 5000/12 ms, resolution = 700 x 270 x 270 
µm), slice thickness 0.7mm, 12 slices total . To acquire T1-contrast MRI scans, the animals were 
then removed from the scanner and injected with 100 μl of the contrast agent gadolinium 
(Magnevist, Bayer, #NDC 50419-188-01) intravenously (i.v.). Animals were then repositioned 
within the scanner for a post-contrast T1-weighted spin echo scan (TR/TE = 1000/14 ms, 
resolution = 700 x 270 x 270 µm). The average total examination time for each animal, including 
both T2 and T1, was 30 to 35 min. Tumor boundaries were manually determined based on hypo-
intense regions in T2-weighted images. Total volume was determined from multi-slice T2-
weighted MR data. In this model, T2-weighted hypo-intensities have been previously confirmed 
by histology to correlate with tumor tissue.7 Volumes of interest were contoured around the 
enhancing rim of tumors on the contrast-enhancing T1 images for volume measurements as 
described. 8 Tumor volume and gender were used to randomize mice into treatment and vehicle 
groups. 
Hoechst dye assay 
Tumor-bearing mice were treated with B20-4.1.1 or vehicle for 6 days (two dose of 5 mg/kg, 3 
days apart). At post-treatment day 6, animals were i.v. injected with 50 μl of DyLight488-labeled 
Lectin (Vector, #DL-1174, 2 mg/ml). After 5 min, mice were i.v. injected with a 2 mg/ml (50 μl) 
aqueous solution of Hoechst 33342 (Sigma, #H6024). After 5 min, mice were euthanized and 
perfused with fresh 4% paraformaldehyde (PFA) solution (Electron Microscopy Sciences, 
#15714). The brain was extracted and fixed in 4% PFA overnight and then transferred to a 30% 
sucrose solution in PBS for at least 72 h. Brains were cut into 40 µm slices using a Leica 
SM2010 R microtome. For confocal microscopy (Leica CTR6500), slices were washed in PBS 
and mounted onto a glass slide with anti-fade mounting medium and further analyzed. For 
quantification, at least 5 representative 10X images per tumor were taken to obtain the average 
number of positive cells per tumor and areas positive for Hoechst were quantified using ImageJ. 
At least 3 tumors were included in the B20-4.1.1 and vehicle groups.  
 
TUNEL assay 
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays 
for optical microscopy were performed on 5 µm sections using a Terminal Transferase 
recombinant kit (Roche, #3333566). Fluorescent TUNEL assays were performed using the In 
Situ Cell Detection Kit, TMR red (Roche, #12156792910). 
 
Tissue processing 
Animals were sedated with i.p. injections of ketamine (0.1 mg/g) and xylazine (0.02 mg/g), 
perfused with ice-cold Ringer’s solution, and sacrificed. Brains were fixed in 10% neutral-
buffered formalin for 72 h at room temperature, processed in a tissue processer (Leica TP1050), 
embedded in paraffin, sectioned (5 μm), and slide-mounted for immunohistochemistry (IHC) and 
immunofluorescence staining. Sections were deparaffinized in Histo-Clear (Richard-Allan 
Scientific, Walldorf, Germany) and were passed through graded alcohols before staining with a 
hematoxylin and eosin (H&E) reagent. 
Immunohistochemistry  
IHC staining was performed using an automated staining processor (Ventana Discovery XT 
Roche Inc., Tucson, AZ). The following primary antibodies were used at the following dilutions: 
rabbit polyclonal anti-Iba1, 1:250 (Wako, #019-19741); rabbit polyclonal anti-Olig2, 1:250 
(Millipore, #AB9610); mouse monoclonal anti-PCNA, 1:2000 (DAKO, #M0879); rabbit 
polyclonal anti-phospho-Histone H3, 1:500 (Millipore, #06-570); rat monoclonal anti-CD31, 
1:50 (Dianova, #DIA 310); rabbit polyclonal anti-KI67, 1:100 (Vector Laboratories, #VP-K451) 
and rabbit polyclonal anti-cleaved caspase 3 1:100 (Cell Signaling, #9661). Nuclei were 
counterstained with hematoxylin. Slides were visualized using a Leica DM5500 B widefield 
microscope. For quantification, 5 representative 20X images were taken for each tumor to obtain 
the average number of positive cells per tumor and were quantified using ImageJ. For some 
quantification, slides were scanned using a Spectrum system from Aperio and analyzed using 
ImageScop v11.1.2.760 (Aperio). Tumor regions were selected based on H&E staining and 
percent positivity was based on the percentage of total nuclei that were deemed positive by pixel 
density.  
 
Immunofluorescence 
Paraffin-embedded sections (5 μm) were deparaffinized in Histo-Clear (Richard-Allan Scientific 
# 6901) and passed through graded alcohols. Next, we performed antigen retrieval with citric 
acid (vector lab #H-3300) in a boiling water bath for 15 min. After two washes in PBS and 
permeabilization in 0.3% triton in 0.1 M PBS for 45 min, sections were incubated in 0.1 M PBS 
containing 2% BSA, 5% NDS, and 0.1% Triton for 1 h at room temperature. For staining, 
sections were incubated with the following antibodies overnight at 4°C in PBS plus 1% BSA: 
rabbit polyclonal anti-Iba1, 1:200 (Wako Pure Chemicals, #019-19741); rabbit polyclonal anti-
Olig2, 1:200 (Millipore, #AB9610); rat monoclonal anti-CD31, 1:50 (Dianova, #DIA 310); 
mouse monoclonal anti-GFAP, 1:1000 (Merck Millipore, #MAB360);. Secondary antibodies 
were conjugated to different Alexa-Fluor dyes (488, 555, 568 and 647) and used at a dilution of 
1:500 in PBS. Nuclear counterstaining was performed with DAPI (Sigma, #D9542). Slides were 
visualized using a Leica CTR6500 microscope. For quantification, at least 5 representative 20X 
images for each tumor were taken to obtain the average number of positive cells per tumor and 
were quantified using ImageJ.  
 
Bioluminescence imaging (BLI) 
Mice were anesthetized with 3% isoflurane. The hair covering the head was shaved before retro-
orbital injection with 75 mg/kg body weight of D-luciferin (30 mg/ml dH2O at 2.5 μl per gram 
mouse weight). One min after injection of D-luciferin, images were acquired for 5 min for Gli-
luc;Ntv-a;Ink4a-Arf-/- and 15 min for Nestin-tv-a;E2F1-Luc mice with an IVIS 100 (Xenogen) 
imaging system. A photographic image was taken, onto which the pseudocolor image 
representing the spatial distribution of photon count was projected. A circular region (1.5 cm 
diameter) of interest (ROI) covering the tumor region was defined and used to quantify the 
bioluminescent signals in all experiments. All representative images were formatted using the 
same maximum and minimum threshold parameters. DEX-treated mice were treated 
immediately after imaging on Day 0, and subsequently were treated 1 h before imaging on days 
1 and 2. BLI was also used for monitoring the response to treatment. Tumor growth was 
monitored every 5 days using BLI. As soon as tumor-bearing mice produced a signal equal to at 
least 103 photons/sec, they were randomized into different treatment or vehicle groups.  
 
Quantification of total vessel area and average vessel size 
 
CD31+ vessels were quantified by counting vessel numbers and using the freehand tool with 
ImageJ and Fiji software to determine total area covered by vessels-total vessel area (excluding 
lumens). Average vessel size was calculated from total area and vessel density per 20X field. At 
least five and up to 15 20X images were analyzed per tumor to obtain representative values per 
tumor sample.   
 
Quantification of necrotic areas 
Paraffin-embedded tumor sections were stained with H&E. Subsequently, slides were scanned 
using a Spectrum system from Aperio and analyzed using ImageScop v11.1.2.760 (Aperio). The 
tumor region, as well as regions of necrosis, were selected and the necrotic index was calculated 
according to the following formula; Necrotic index = Area of necrosis (μm2)/Total area of tumor 
section (μm2)9. 
 
Radiation treatment (RT) 
Mice were lightly sedated with ketamine (0.1 mg/g) and xylazine (0.02 mg/g) and were 
irradiated using a Pantak X-RAD 320 x-ray unit (PXI, North Branford, CT). Only the head was 
irradiated; the rest of the mouse was shielded with a specialized lead jig. The total dose and 
schedules are described in detail in Figures 5.  
 
Primary glioma cell cultures 
Glioma-bearing mice were euthanized and transcardially perfused with ice-cold PBS. The tumor 
was grossly dissected and enzymatically digested in Hanks balanced salt solution containing 
12% papain and 10 μg/ml DNase at 37˚C for 15 min, with subsequent inactivation using 
ovomucoid (1 mg/mL) (Worthington, Lakewood, NJ). The resulting single cell suspension was 
resuspended in DMEM media containing 10% FBS, 2mM L-glutamine, 100 units/mL penicillin, 
and 100 µg/mL streptomycin. In order to mimic in vivo conditions, the primary cultures were 
treated with physiologically relevant, low and high concentrations (i.e. 0.1, 1 and 10 μM = 39.5 
ng/ml, 395 ng/ml and 3950 ng/ml) of DEX. The cultures used in these experiments were freshly 
isolated from tumors and passaged in serum a maximum of 5 times. 
 
MTT assays 
Cell viability was measured using MTT assays (Sigma No. M5655). Primary glioma cultures 
were seeded at a density of 1000 per well in 96-well plates. A 50 mM stock solution of DEX 
(Sigma D4902) was prepared by dissolving the drug in DMSO. Cells were allowed to attach 
overnight and DEX or vehicle control was added to the appropriate wells. After 3 days of drug 
exposure, MTT was added and allowed to incubate for 3 h. Afterwards, the media was aspirated 
and the purple formazan crystals were dissolved in 100 μl DMSO (Fisher). Absorbance was 
measured at wavelengths of 570/690 nm using a FLx800 fluorescence microplate reader (BioTek 
Instruments, Inc.).  
 
Cell cycle analysis 
Primary glioma cultures were seeded at a density of 4000 cells/mL in 10 cm plates. Cells were 
allowed to attach to the plates overnight and then treated with DMSO or 0.1, 1 and 10 μM DEX 
for 3 days. After trypsinization and washing in ice-cold PBS, cells were fixed in ice-cold 70% 
ethanol for at least 1 h. Subsequently, cells were washed with PBS and stained with 0.05 mg/ml 
propidium iodide (PI) in the presence of 0.1 mg/ml RNase and then analyzed using a BD Accuri 
C6 flow cytometer. Quantification of different phases of the cell cycle (G0/G1, S, G2/M) was 
performed using Modfit LT. 
 
Microarray analysis 
Gliomas were grossly dissected from four untreated and four DEX-treated (3 days @ 10 mg/kg) 
mice. Upon dissection, tissue was flash-frozen in liquid nitrogen, homogenized, and dissolved in 
Trizol (Invitrogen, Carlsbad, CA). RNA was extracted and processed for Illumina mouse-ref 8 
array platform. Array data were analyzed using Partek analysis software. ANOVA statistics were 
run to determine significantly altered genes. The DEX gene signature was generated using an 
unadjusted p-value of p > 5x10-4. Gene lists were uploaded into Ingenuity Pathway Analysis 
(www.ingenuity.com) for analysis of relevant pathways. 
 
qRT-PCR 
Total RNA was extracted from control and DEX-treated mouse tumor samples using Trizol 
reagent (Invitrogen). The yield and purity of the RNA was confirmed using Nanodrop; ND-1000 
V3, spectrophotometer. cDNA was synthetized using transcriptor first strand cDNA synthesis kit 
using 1 μg of RNA (Roche Applied Sciences, Indianapolis, MN). Primers were designed using 
the Roche Universal Probe Library. The following primers were used: Aurka 5′-
TTGCAGACTTCGGGTGGT-3′ (forward) and 5′-TCCAGGGTGCCACACATT-3′ (reverse), 
Bub1b 5′-TTACGCCGTACGTGGAAGA-3′ (forward) and 5′-GCTCAATCTTGCATGGTGTC-
3′ (reverse), Ccnb1 5′-TGCATTTTGCTCCTTCTCAA-3′ (forward) and 5′-
CAGGAAGCAGGGAGTCTTCA-3′ (reverse), cdc20 5′-ACATCAAGGGCGCTGTCAAG-3′ 
(forward) and 5′-AATGTGCCGGTCACTGGT-3′ (reverse), Cenpa 5′-
CAAGGAGGAGACCCTCCAG -3′ (forward) and 5′-TTCTGTCTTCTGCGCAGTGT-3′ 
(reverse), Kif2c 5′-CGAAGGAGGTACCACAAAAGG-3′ (forward) and 5′-
TTCGGTCGTAAGGGAAGAAG-3′ (reverse), Plk1 5′-TTGTAGTTTTGGAGCTCTGTCG-3′ 
(forward) and 5′-AGTGCCTTCCTCCTCTTGTG-3′ (reverse), TBP 5′-
GGCCTCTCAGAAGCATCACTA-3′ (forward) and 5′-GCCAAGCCCTGAGCATAA-3′ 
(reverse), 
The housekeeping gene, TATA-binding protein (TBP), was used for normalization. The qRT-
PCR was performed using a LC480 light cycler under the following conditions; activation cycle 
for 5 min at 95°C, followed by 50 cycles of amplification. Each amplification cycle started with 
an activation step for 5 min at 95°C, an annealing step for 30 sec at 60°C, and finally an 
extension step at 72°C for 10 sec.  
 
TCGA analysis 
Expression values for each gene of interest were obtained from the MSKCC computational 
biology cancer genomics portal (http://www.cbioportal.org/cgx/index.do) which has annotated 
TCGA data 10,11. Survival data were obtained from the TCGA data portal (https://tcga-
data.nci.nih.gov/tcga/).  
 
Retrospective clinical analyses 
A retrospective clinical analysis was performed with permission from the Institutional Review 
Board of MSKCC. Adult patients (>18 years old) at the time of histologic diagnosis of a 
glioblastoma who underwent external beam radiotherapy between 1998 and 2008 were eligible 
for the study. From initial 677 pathologically confirmed glioblastomas, 55 were excluded (17 
patients ≤18 years of age, 1 patient with brainstem glioma, 10 patients missing decisive RPA 
information and 27 patients with unknown DEX status at start of RT).Patients were not eligible 
for the study if more than one of the clinical or treatment characteristics listed were missing from 
the medical records. Clinical characteristics of patients were recorded, including: age at 
diagnosis, Karnofsky performance score (KPS), mental status (mini-mental status from initial encounter or description of patient interaction from first encounter), neurologic functional 
status (defined as “working” or “not working” at time of diagnosis, as described in the original RTOG RPA analysis), and duration of symptoms before diagnosis. Treatment 
characteristics were recorded, including: extent of surgery (biopsy, subtotal resection, or gross 
total resection), RT dose and fractionation, use of corticosteroids at the start of RT, and use of 
temozolomide during RT. Clinical and treatment characteristics were used to group patients 
according the Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) 
classification system12,13. Categorical multivariate cox regression models were constructed 
correlating RTOG RPA class, initial chemotherapy use, and baseline corticosteroid use with 
clinical outcomes.  
 
In the retrospective clinical analysis of 573 patients from the EORTC 26981/22981 trial, 
correlation analyses of baseline steroid use and dose with outcomes were performed by 
univariate and multivariate Cox regression models. In the whole population, all models were 
stratified by treatment and all multivariate models were adjusted for main prognostic factors 
(age, extent of surgery, performance status). In this subgroup study, all analyses were performed 
at an exploratory 5% significance level. P-values higher than 5% but lower than 10% were 
considered as “borderline non-significant”. 
 
We also studied 832 patients with glioblastoma enrolled in the German Glioma Network (GGN) 
(www.gliomnetzwerk.de). Diagnosis for all patients was confirmed by central pathology review 
according to the WHO classification of tumors of the central nervous system. Inclusion criteria 
for this analysis were RT alone or RT plus chemotherapy (TMZ in all but 17 patients) as the 
first-line therapy as well as documentation about medication with steroids during radiotherapy 
(yes or no). Progression-free survival (PFS) was calculated from the day of first surgery until 
progression, death or the end of follow-up. Overall survival (OS) was calculated from the day of 
first surgery until death or the end of follow-up. Logrank tests were used to compare outcome 
data. Cox regression models were built to assess the independent association of steroid use with 
OS adjusted for relevant clinical parameters. 
 
Statistical analysis 
Graphs were created using GraphPad Prism 6 (GraphPad Software, San Diego, CA) and were 
analyzed as noted in the figure legends. Cox proportional hazards analysis was performed in the 
survival package ‘survival’ version 2.36-1014 in the R studio software15. In the retrospective 
clinical analysis of EORTC 26981/22981 trial, SAS 9.4 was used, in particular the PHREG 
procedure for Cox modeling. *=p<0.05, **=p<0.01, ***=p<0.001, no asterisks = not significant. 
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Supplemental legends 
 
SFigure 1. DEX-treatment decreases proliferation but does not enhance glioma cell death. 
A) Representative immunohistochemical staining for Ki67 in vehicle and DEX-treated mice. 
Corresponding bar graph shows that DEX-treatment induces significant decrease in proliferation 
compared to Vehicle-treated tumors. B) Representative immunohistochemical staining for 
cleaved caspase-3 (an apoptotic marker) and H&E in vehicle- and DEX-treated mice. 
Corresponding bar graphs show quantification of % of CC3+positive cells and necrotic index 
(Necrotic index = Area of necrosis (μm2)/Total area of tumor section (μm2)* per 40X field within 
the tumor). No differences were observed with DEX treatment. N = 5 for all samples, p values 
were calculated with a Student’s t-test. Scale bars: 50 μm for A. 
 
SFigure 2. DEX does not suppress proliferation in vitro. (A) In vitro MTT assay of three 
independent primary murine glioma cultures treated with 0.1, 1 and 10 μM of DEX did not show 
a reduction in cell proliferation. (B) In vitro cell cycle analysis of primary murine glioma 
cultures treated with 3 days of 0.1, 1 and 10 μM of DEX showed that DEX induced a slight but  
significant increase in the G1 population (from 50.97% in vehicle to 54.19 - 54.82% with DEX), 
with a corresponding decrease in the G2 population (from 34.45% in vehicle to 30.17 - 30.53% 
with DEX). However, the magnitude of these changes was not as large as anticipated based on 
the in vivo BLI and IHC responses. p values were calculated using a one-way ANOVA in 
comparison to DMSO, * p<.05, **p<.01, *** p<0.001. 
 
SFigure 3. B20-4.1.1 treatment has no effect on non-tumor vasculature, decreases edema by 
T1-contrast MRI and increases myeloid cell infiltration in contrast to DEX. A) 
Representative images of CD31 staining of a non-tumor cortical area in vehicle- and B20-4.1.1-
treated mice and corresponding graphs showing no significant differences in either total vessel 
area or average vessel size between B20-4.1.1- and vehicle-treated mice. B) Representative 
images of T1-contrast MRI scans of vehicle- and B20-4.1.1-treated mice. Graphs comparing 
tumor volumes according to T1-contrast MRI scans in vehicle- and B20-4.1.1-treated mice at the 
endpoint of survival, demonstrating a statistically significant difference in tumor size between 
vehicle- and B20-4.1.1-treated animals. C) Representative images of Iba1 staining for tumor-
associated microglia/macrophages in vehicle and B20-4.1.1-treated mice (upper panel) and 
vehicle and DEX treated tumors.  Graphs comparing the total Iba1 positive areas in vehicles and 
B20-4.1.1 and DEX treated mice show that while there is significant increase in macrophage 
infiltration in B20-4.1.1 treated mice compare to vehicle, no significant difference was observed 
in DEX-treated compare to vehicle-treated mice. p values were calculated using an unpaired 
Student’s t-test, *p<0.05 **p < 0.01, ****p < 0.0001: Scale bars: 50 μm for A and C.  
 
SFigure 4. Olig2-positive tumor cells showed a significant increase in cell death in response 
to B20-4.1.1 treatment. (A) Representative images of tumor sections and (B) corresponding 
quantification of cell death by TUNEL staining in Olig2-positive gliomas and CD31-positive 
endothelial cell populations. While there were no significant differences in the percentage of cell 
death of CD31-positive endothelial cells, there was a significant increase in the percentage of 
cell death of Olig2-positive tumor cells. n = 4 and 5 for vehicle and B20-4.1.1, respectively. p 
values were calculated with an unpaired Student’s t-test, *p < 0.05. Scale bars: 50 μm. 
 
STable 1. Patient and treatment characteristics, categorized by use of DEX at the start of 
radiotherapy. A) The median survival of all patients was 13.6 months (0.76-116.6 months) and 
595 of the patients (96%) have died at the time of analysis. The median overall survival was 
18.7, 18.4, 11.8, and 5.1 months in RTOG RPA classes III, IV, V, and VI, respectively 
(p<0.0001). B) Multivariate COX regression analysis of glioblastoma patients treated at 
MSKCC, examining RTOG RPA Class, concurrent TMZ, and DEX at the start of radiotherapy.   
 
STable 2. Patient and treatment characteristics, categorized by use of DEX at the start of 
radiotherapy for GGN (A) and EORTC (B). 
 
STable 3. A) PFS and OS in the GGN cohort by steroid use. B) Multivariate analysis of the 
association of steroid administration and outcome in the GGN cohort 
 
STable 4. Genes and top predicted cellular functions and canonical pathways of DEX 
regulated gene set.. A) The 25 most significantly changed probes on an illumina mouse-ref-8 
array. The gene list is based on a greater than 1.5 fold change, with an ANOVA p value < 
0.0005. This list was generated using Partek Genomics Suite array analysis software (v6.6). B) 
Gene ontology analysis of DEX-regulated genes. The top 5 most enriched predicted cellular 
function and canonical pathways, based on the 19 DEX-regulated genes. 
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Table S1.	  Pa?ent	  and	  treatment	  characteris?cs	  with	  or	  without	  	  
	  DEX	  at	  the	  start	  of	  radiotherapy	  
^p	  value	  calculated	  using	  Chi	  squared	  test	  
KPS	  -­‐	  Karnofsky	  Performance	  Status;	  STR	  -­‐	  Subtotal	  ResecAon	  
GTR	  -­‐	  Gross	  Total	  ResecAon,	  RTOG	  –	  RadiaAon	  Therapy	  Oncology	  Group	  
RPA	  -­‐	  Recursive	  ParAAoning	  Analysis;	  TMZ	  -­‐	  Temozolomide	  
A
B	  
Characteris?c	  
N	  =	  522	  (84%)	  
+Steroid	  
N=	  100	  (16%)	  
-­‐Steroid	   p	  value^	  
Sex	  n	  (%)	   	  	  
	  	   M	   326	  (62.5%)	   70	  (70%)	   0.1505	  
	  	   F	   196	  (37.5%)	   30	  (30%)	   	  	  
Age,	  y	   	  	   	   	   	  	  
	  	   Median	   59	   56	   	  	  
Age,	  n	  (%)	   	  	   	   	   	  	  
	  	   <50	   130	  (24.9%)	   27	  (27%)	   0.7063	  
	  	   ≥50	   392	  (75.1%)	   73	  (73%)	   	  	  
KPS,	  n	  (%)	   	  	  
	  	   ≥90	   201	  (38.5%)	   68	  (68%)	   <	  0.0001	  
	  	   ≥70	  -­‐	  <90	   231	  (44.3%)	   28	  (28%)	   	  	  
	  	   <70	   90	  (17.2%)	   4	  (4%)	   	  	  
Mental	  Satus,	  n	  (%)	   	   	   	  	  
	  	   Normal	   376	  (72%)	   85	  (85%)	   0.0207	  
	  	   Abnormal	   140	  (26.8%)	   15	  (15%)	   	  	  
	  	   Data	  Missing	   6	  (1.1%)	   0	  (0%)	   	  	  
Symptom	  Length	   	  	  
	  	   <12	  wk	   405	  (77.6%)	   76	  (76%)	   0.7285	  
	  	   ≥12	  wk	   117	  (22.4%)	   24	  (24%)	   	  	  
Neurologic	  func?onal	  status,	  n	  (%)	   	   	  	  
	  	   Working	   162	  (31%)	   57	  (57%)	   <	  0.0001	  
	  	   Not	  Working	   357	  (68.4%)	   43	  (43%)	   	  	  
	  	   Data	  Missing	   3	  (0.6%)	   0	  (0%)	   	  	  
Surgical	  Extent	   	  	  
	  	   Biopsy	   97	  (18.6%)	   9	  (9%)	   0.0032	  
	  	   ResecAon	   	  	  
	  	   STR	   231	  (44.3%)	   37	  (37%)	   	  	  
	  	   GTR	   194	  (37.2%)	   54	  (54%)	   	  	  
Radia?on	  Dose	   	   	   	  	  
	  	   >54.4	  Gy	   407	  (78%)	   90	  (90%)	   0.0019	  
	  	   ≤54.4	   105	  (20.1%)	   6	  (6%)	   	  	  
	  	   Data	  Missing	   10	  (1.9%)	   4	  (4%)	   	  	  
RPA	  Class	   	  	  
	  	   Class	  3	   72	  (13.8%)	   23	  (23%)	   0.0004	  
	  	   Class	  4	   145	  (27.8%)	   40	  (40%)	   	  	  
	  	   Class	  5	   243	  (46.6%)	   34	  (34%)	   	  	  
	  	   Class	  6	   62	  (11.9%)	   3	  (3%)	   	  	  
Concurrent	  Chemotherapy	   	   	   	  	  
	  	   TMZ	   166	  (31.8%)	   46	  (46%)	   0.1381	  
	  	   No	  TMZ	   359	  (67.5%)	   51	  (56.7%)	   	  	  
Cox	  propor?onal	  mul?variate	  hazards	  analysis	  of	  p?ent	  prognos?c	  survival	  
factors	  
Variables	   p	  value	   HR	   95%	  CI	  
Dexamethasone	   p	  =	  0.00034	   1.512	   1.2058	  -­‐	  1.8960	  
RTOG	  RPA	  Class	   p	  <	  0.0001	   1.5461	   1.3989	  -­‐	  1.7088	  
Temozolomide	   p	  =	  0.00096	   0.749	   0.6312	  -­‐	  0.8892	  
HR = hazard ratio    CI = confidence interval  
RTOG - Radiation Therapy Oncology Group 
RPA - Recursive Partitioning Analysis 
Characteris?cs	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  Steroids	  at	  baseline	  
Total	  
(N=573)	  
Missing	  
N=1	  (0.17%)	  
No	  
N=164	  (28.6%)	  
Yes	  
N=408	  (71.2%)	  
Treatment	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  RT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  (100.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  70	  (42.7)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  215	  (52.7)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  286	  (49.9)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  TMZ/RT	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0	  (0.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  94	  (57.3)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  193 (47.3)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  287	  (50.1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
WHO	  Performance	  
Status	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  0	  (0.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  80	  (48.8)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  143 (35.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  223	  (38.9)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  >0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  (100.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  84	  (51.2)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  265	  (65.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  350	  (61.1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Extent	  of	  surgery	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Biopsy	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  0	  (0.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  (4.9)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  85	  (20.8) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  93	  (16.2) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ParAal	  ResecAon	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  0	  (0.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  65	  (39.6)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  189 (46.3)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  254	  (44.3)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Complete	  ResecAon	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  1	  (100.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  91	  (55.5)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  134	  (32.8)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  226	  (39.4)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Age	  (conAnuous)	   	   	   	   	  
	  Median	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  62.4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   54.0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   56.7	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   55.8
	  Range	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  62.4	  -­‐	  62.4	  	  	  	  	  	  	  	   19.0	  -­‐	  70.8 18.6	  -­‐	  70.5	  	  	  	  	  	  	  	   18.6 -­‐	  70.8	  	  	  	  	  	  	  	  
	  N	  obs	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   164	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   408	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   573	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Age	  (class)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  <=50	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0	  (0.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  23	  (14.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  41	  (10.0) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  64	  (11.2)	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  0	  (0.0)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  99	  (60.4)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  240 (58.8)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  339	  (59.2)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  >60	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	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  42	  (25.6)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  127	  (31.1)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  170	  (29.7)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
last	  daily	  dose	  
administered	  	  (mg)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  Median	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   8.0	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   8.0 	  	  	  	  	  	  	  	  	  	  
	  Range	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   1.0	  -­‐	  160.0	  	  	  	  	  	  	  	   1.0	  -­‐	  160.0	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Tercile1	   	   	   	   1-­‐4	  
	  Median	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B
Pa?ent	  and	  treatment	  characteris?cs	  with	  or	  without	  	  
	  	  	  	  	  	  	  DEX	  at	  the	  start	  of	  radiotherapy	  in	  EORTC	  (A)	  and	  GGN	  (B)	  
Table S2.	  
Characteris?cs	  
Steroids	  
N=370	  
(44.5%)	  
No	  Steroids	  
N=462	  
(55.5%)	  
p-­‐value	  
Gender	   	  	   	  	  
0.254	  	  	  Male	   213	  (57.6%)	   284	  (61.5%)	  
	  	  Female	   157	  (42.4%)	   178	  (38.5%)	  
Age,	  y	   	  	   	  	  
	  
0.194	  
	  
	  
	  	  Median	  (range)	   63	  (19	  -­‐	  83)	   60	  (22	  -­‐	  86)	  
	  	  	  	  	  ≤60	  y	   158	  (42.7%)	   233	  (50.4%)	  
	  	  	  	  	  >60	  y	   212	  (57.3%)	   229	  (49.6%)	  
KPS	   	  	   	  	  
0.238	  
	  	  <70	   28	  (7.6%)	   22	  (4.8%)	  
	  	  70-­‐80	   180	  (48.6%)	   233	  (50.4%)	  
	  	  ≥90	   162	  (43.8%)	   207	  (44.8%)	  
Surgical	  Extent	   	  	   	  	  
0.001	  
	  	  biopsy	   92	  (24.9%)	   72	  (15.6%)	  
	  	  parAal	   48	  (13.0%)	   43	  (9.3%)	  
	  	  subtotal	   113	  (30.5%)	   163	  (35.3%)	  
	  	  total	   117	  (31.6%)	   184	  (39.8%)	  
RadiaAon	  Dose	   	  	   	  	  
0.152	  
	  	  ≤54	  Gy	   43	  (13.2%)	   37	  (9.8%)	  
	  	  >54	  Gy	   282	  (86.8%)	   341	  (90.2%)	  
	  	  Data	  Missing	   45	   84	  
Therapy	   	  	   	  	  
0.555	  	  	  RT	   77	  (20.8%)	   104	  (22.5%)	  
	  	  RT+CT	   293	  (79.2%)	   358	  (77.5%)	  
A
Table	  S3.	  A)	  PFS	  and	  OS	  in	  the	  GGN	  cohort	  by	  steroid	  use.	  B)	  Mul?variate	  analysis	  of	  the	  
associa?on	  of	  steroid	  administra?on	  and	  outcome	  in	  the	  GGN	  cohort.	  
	  
	   	  	   N	  (events)	  
PFS	  
Median	  in	  months	  (95%	  
CI)	  
Events	  
PFS	  
Median	  in	  months	  
(95%	  CI)	  
Events	  
HR,	  	  
p	  value	  
OS	  
Median	  in	  months	  
(95%	  CI)	  
Events	  
OS	  
Median	  in	  months	  
(95%	  CI)	  
Events	  
HR,	  	  
p	  value	  
Steroids	   	   -­‐	   +	   	   -­‐	   +	   	  
Events	   	   	   	   	   	   	   	  
All	  paAents	  
&	  events	  
832	  	  
7.0	  
(6.5-­‐7.6)	  
441/462	  
6.1	  
(5.5-­‐6.8)	  
358/370	  
1.21	  
0.008	  
15.7	  
(14.0-­‐17.4)	  
408/462	  
12.1	  
(10.9-­‐13.2)	  
337/370	  
1.32	  
<0.001	  
RT	  only	   181	  
5.6	  	  
(4.8-­‐6.5)	  
102/104	  
4.9	  	  
(4.2-­‐5.6)	  
75/77	  
1.21	  
0.215	  
	  
8.8	  
(7.1-­‐10.5)	  
99/104	  
6.8	  
(5.7-­‐8.0)	  
74/77	  
1.23	  
0.178	  
	  
RT/CT	   651	  
7.5	  
(6.6-­‐8.5)	  
339/358	  
6.7	  
(5.9-­‐7.5)	  
283/293	  
1.23	  
0.010	  
18.8	  
(16.8-­‐20.7)	  
309/358	  
13.3	  
(11.7-­‐14.9)	  
263/293	  
1.37	  
<0.001	  
GTR	   301	  
9.5	  
(7.7-­‐11.4)	  
171/184	  
6.7	  
(5.6-­‐7.7)	  
114/117	  
1.51	  
0.001	  
22.1	  
(18.7-­‐25.5)	  
158/184	  
15.0	  
(13.2-­‐16.8)	  
105/117	  
1.40	  
0.008	  
No	  GTR	   531	  
6.1	  
(5.3-­‐6.9)	  
270/278	  
5.6	  
(4.8-­‐6.4)	  
244/253	  
1.00	  
0.992	  
12.8	  
(11.1-­‐14.4)	  
250/278	  
10.4	  
(8.7-­‐12.0)	  
232/253	  
1.12	  
0.048	  
GTR	   	   	   	   	   	   	   	  
RT	  only	   51	  
5.8	  
(3.8-­‐7.7)	  
33/34	  
5.4	  
(3.7-­‐7.2)	  
17/17	  
1.05	  
0.863	  
9.9	  
(8.0-­‐11.8)	  
32/34	  
10.9	  
(6.0-­‐15.7)	  
17/17	  
1.20	  
0.539	  
RT/CT	  only	   250	  
11.1	  
(9.3-­‐13.0)	  
138/150	  
6.7	  
(5.1-­‐8.3)	  
97/100	  
1.60	  
<0.001	  
24.5	  
(20.3-­‐28.7)	  
126/150	  
15.3	  
(13.4-­‐17.2)	  
88/100	  
1.47	  
0.006	  
No	  GTR	   	   	   	   	   	   	   	  
RT	  only	   130	  
5.3	  
(4.2-­‐6.4)	  
69/70	  
4.5	  
(3.3-­‐5.6)	  
58/60	  
1.24	  
0.239	  
8.0	  
(6.2-­‐9.8)	  
67/70	  
6.4	  
(4.8-­‐8.0)	  
57/60	  
1.20	  
0.320	  
RT/CT	  only	   401	  
6.4	  
(5.5-­‐7.3)	  
201/208	  
6.5	  
(5.3-­‐7.6)	  
186/193	  
0.98	  
0.844	  
15.2	  
(13.1-­‐17.3)	  
183/208	  
12.1	  
(10.7-­‐13.4)	  
175/193	  
1.23	  
0.048	  
Factor	   HR	   95%	  CI	   P	  value	  
Steroids	  Yes	  vs.	  no	  (ref.)	   1.18	   1.02	  -­‐	  1.37	   0.024	  
Therapy	  RT	  vs.	  RT/CT	  (ref.)	   1.75	   1.47	  -­‐	  2.09	   <0.001	  
Resec?on	  No	  gross	  total	  vs.	  gross	  total	  (ref.)	   1.59	   1.36	  -­‐	  1.85	   <0.001	  
Age	  >60	  vs.	  ≤	  60	  (ref.)	   2.07	   1.78	  -­‐	  2.41	   <0.001	  
KPS	  ≤	  80	  vs.	  >80	  	  (ref.)	   1.17	   1.00	  -­‐	  1.36	   0.041	  
A	  
B	  
Table S4. Genes and top predicted cellular functions and 
 canonical pathways of DEX regulated gene set.  
A	  The	  25	  most	  signiﬁcantly	  changed	  probes	  on	  illumina	  mouse-­‐
ref-­‐8	  array.	  Gene	  list	  based	  on	  a	  greater	  than	  1.5	  fold	  change,	  
with	  an	  ANOVA	  p	  value	  >	  0.0005.	  	  
B	  The	  top	  5-­‐enriched	  predicted	  cellular	  funcAon	  and	  
canonical	  pathways,	  based	  on	  the	  19	  DEX-­‐regulated	  
genes.	  	  
	  	  
Illumina(
Probeset(ID SYMBOL
ANOVA(
p;value
Fold;Change((
(Dex(vs.(
Untreated)
1340056 6720463M24Rik 0.00031 .1.75208
4780193 Aspm 0.00036 .1.59169
380520 Aurka 0.00017 .2.39294
7400215 Birc5 0.00019 .2.15796
2810612 Birc5 0.0003 .2.01431
1240446 Birc5 0.00047 .2.25534
5910528 Bub1b 0.00019 .2.06295
2190164 Ccnb1 6.56E.05 .3.06757
7550156 Ccnb1 0.00047 .3.03562
4610722 Cdc20 0.00012 .3.2905
4390228 Cdc20 0.00019 .2.93043
2320678 Cdc25c 3.38E.05 .1.81601
3830328 Cdc25c 5.71E.05 .2.0114
1050170 Cdca3 7.99E.05 .2.96694
4920148 Cdca3 0.00032 .1.91606
1500446 Cdca8 0.00038 .2.00116
7200519 Cenpa 2.32E.05 .3.48198
2710703 E130306D19Rik 3.77E.05 .1.94952
630634 Incenp 0.00016 .1.9118
4210246 Kif22 8.05E.05 .2.67197
1780543 Kif2c 0.00011 .2.61431
6940411 Pif1 8.06E.05 .2.43358
520427 Plk1 0.00012 .2.58357
780475 Prc1 0.00049 .2.65046
6620184 Spc25 0.00029 .1.94168
Predicted	  Cellular	  Func?ons	   	  p-­‐value	   Molecules	  
Cell	  Cycle	   1.97E-­‐17	  -­‐	  3.87E-­‐02	  
CDC25C,	  CDCA8,	  CDC20,	  
PRC1,	  PLK1,	  AURKA,	  BUB1B,	  
BIRC5,	  CCNB1,	  KIF22,	  
ASPM,	  CENPA,	  KIF2C,	  
INCENP	  
Cellular	  Assembly	  and	  OrganizaAon	   1.94E-­‐11	  -­‐	  3.87E-­‐02	  
CDC25C,	  CDCA8,	  CDC20,	  
PRC1,	  PLK1,	  AURKA,	  BUB1B,	  
BIRC5,	  PIF1,	  CCNB1,	  KIF22,	  
CENPA,	  KIF2C,	  INCENP	  
DNA	  ReplicaAon,	  RecombinaAon,	  and	  
Repair	   1.94E-­‐11-­‐3.78E-­‐02	  
CDC25C,	  CDCA8,	  CDC20,	  
PRC1,	  PLK1,	  AURKA,	  BUB1B,	  
BIRC5,	  CCNB1	  KIF22,	  
CENPA,	  KIF2C,	  INCENP	  
Cellular	  Movement	   2.49E-­‐11-­‐3.36E-­‐02	   CDC20,	  PRC1,	  PLK1,	  AURKA,	  BIRC5,	  CCNB1,	  INCENP	  
Cancer	   1.22E-­‐09-­‐3.91E-­‐02	  
CDC25C,	  CDCA8,	  CDC20,	  
PRC1,	  PLK1,	  AURKA,	  	  
BUB1B,	  BIRC5,	  CCNB1,	  	  
KIF22,	  ASPM,	  CENPA,	  KIF2C,	  
INCENP	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Ingenuity	  Canonical	  Pathways	   	  -­‐log(p-­‐value)	   Molecules	  
MitoAc	  Roles	  of	  Polo-­‐Like	  Kinase	   8.64E+00	   CDC25C,	  CDC20,	  PRC1,	  PLK1,	  CCNB1	  
Cell	  Cycle:	  G2/M	  DNA	  Damage	  
Checkpoint	  RegulaAon	   5.15E+00	   CDC25C,	  PLK1,	  CCNB1	  
Role	  of	  CHK	  Proteins	  in	  Cell	  Cycle	  
Checkpoint	  Control	   2.99E+00	   CDC25C,	  PLK1	  
ATM	  Signaling	   2.91E+00	   CDC25C,	  CCNB1	  
Hereditary	  Breast	  Cancer	  Signaling	   2.35E+00	   CDC25C,	  CCNB1	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